NCT06218290Phase 2Completed

A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

Study sponsor: Unicycive Therapeutics, Inc · UNCY

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-05-29Actual

Enrollment · participants106Actual

Source updated2024-06-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chronic Kidney Disease Requiring Chronic Dialysis

Treatments or interventions studied

Oxylanthanum CarbonateDrugAlso known as OLC

Primary outcomes · main study measures

measure: Incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period.; description: Tolerability of clinically effective doses of OLC as assessed by the incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period.; timeFrame: 4 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history